Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03674307 · ClinicalTrials.gov registry record · NA

Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates

A NA study of Cardiovascular Diseases and End Stage Renal Disease, sponsored by University of British Columbia.

Recruiting
Registry status
NA
Development phase
3,306
Enrollment target
20
Study locations

NCT03674307 is a NA study of Cardiovascular Diseases and End Stage Renal Disease that is actively recruiting participants, run by University of British Columbia. The registered enrollment target is 3,306 participants, below the 26,963-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03674307, a NA study of Cardiovascular Diseases and End Stage Renal Disease, is actively recruiting participants, sponsored by University of British Columbia.

RECRUITING
Registry status
NA
Development phase
3,306 participants
Enrollment target
20
Study locations

Study Summary

The Canadian Australasian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease (CARSK) will test the hypothesis that eliminating the regular use of non-invasive screening tests for CAD AFTER waitlist activation is not inferior to regular (i.e., annual) screening for CAD during wait-listing for the prevention of Major Adverse Cardiac Events. Secondary analyses will assess the impact of screening on the rate of transplantation, and the relative cost-effectiveness of screening.

Interventions

  • OTHER No screening
  • OTHER Regular Screening

Study Locations (20)

Ontario

  • St. Joseph's Healthcare - Hamilton
  • Kingston Health Science Centre - Kingston
  • London Health Science Centre - London
  • The Ottawa Hospital Research Institute - Ottawa
  • University Health Network - Toronto
  • St Michael's Hospital - Toronto

Quebec

  • CHU de Quebec-Universite Laval's L'Hotel-Dieu de Quebec - Laval
  • University of Montreal, Maisonneuve-Rosemont Hospital - Montreal
  • McGill University Health Centre - Montreal
  • Universite de Montreal, Hopital Maisonneuve-Rosemont - Montreal

Other

  • Charité Universitätsmedizin - Berlin
  • Sussex Brighton R&D - Brighton
  • King's College Hospital NHS Foundation Trust - Brixton
  • Epsom and St Helier University Hospitals NHS Trust - Carshalton

Arizona

  • University of Arizona - Tucson

District of Columbia

  • The George Washington University - Washington D.C.

Alberta

  • University of Alberta - Edmonton

British Columbia

  • University of British Columbia - Vancouver

Nova Scotia

  • Dalhousie University - Halifax

Trial Details

FieldValue
Enrollment Target 3,306 participants
Start Date 2018-12-01
Est. Completion 2025-12-31
Phase NA

Sponsor

University of British Columbia

18 total trials

What the Registry Record Tells You About NCT03674307

The ClinicalTrials.gov registry entry for NCT03674307 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 3,306 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 26,963-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (88% lower). The listed sponsor is University of British Columbia, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 2 interventions - of which No screening is the first listed.

NCT03674307 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Ontario, Quebec, Other.

Frequently Asked Questions

What is clinical trial NCT03674307 about?

NCT03674307 is a clinical study titled "Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates". The Canadian Australasian Randomized Trial of Screening Kidney Transplant Candidates for Coronary Artery Disease (CARSK) will test the hypothesis that eliminating the regular use of non-invasive screening tests for CAD AFTER waitlist activation is not inferior to regular (i.e., annual) screening for...

What is the current status of trial NCT03674307?

This trial is currently recruiting. It is a NA study. The enrollment target is 3,306 participants. The study started on 2018-12-01. Estimated completion is 2025-12-31.

What conditions does trial NCT03674307 study?

This clinical trial studies the following conditions: Cardiovascular Diseases, End Stage Renal Disease, Kidney Transplantation, Dialysis Related Complication.

What interventions are being tested in trial NCT03674307?

The interventions under investigation include: No screening (OTHER), Regular Screening (OTHER).

Who is sponsoring clinical trial NCT03674307?

This trial is sponsored by University of British Columbia, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03674307 being conducted?

This trial has 20 study locations across Arizona, District of Columbia, Alberta, British Columbia, Nova Scotia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.